🔎 Trials Near Me

Beranda › Melanoma Uveal › Tennessee

Uji klinis Melanoma Uveal di Tennessee

6 studi untuk Melanoma Uveal mencari peserta di lokasi di Tennessee.

Kota di Tennessee

Teks studi resmi (Bahasa Inggris)

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

  • Sarah Cannon Research Institute (SCRI), Nashville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07804186

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

  • Sarah Cannon Research Institute, Nashville
Menerima pesertaFase 1/2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT06940739

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

  • The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Jun 2026 · NCT03947385

Neoadjuvant Darovasertib in Primary Uveal Melanoma

  • SCRI Oncology Partners, Nashville
  • Vanderbilt Eye Institute, Nashville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT07015190

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  • The West Clinic, PLLC dba West Cancer Center, Germantown
  • University of Tennessee Medical Center, Knoxville
  • Sarah Cannon Research Institute, Nashville
  • dan 1 lainnya
Menerima pesertaFase 2/3
Semua usia · Semua jenis kelamin · Diperbarui 2 Apr 2026 · NCT06581406

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

  • SCRI Oncology Partners, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Nov 2025 · NCT07136181

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.